Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Assessment of HPHC Exposure in Smokers Switching to THS/TP18 With Different Device Variants

NCT07443631 · tracked via the Priya Life Science UK tracker
Phase
Not applicable
Started
2026-02-19
Last updated
2026-07-30

Condition(s) studied

Smoking

Investigational drug(s) / intervention(s)

THS1 (TP18 variant 1)THS2 (TP18 variant 2)THS3 (TP18 variant 3)THS4 (TP18 variant 4)THS5 (THS 3.0 reference device)CIG (Cigarette)

THS1 (TP18 variant 1): TP18 prototype variant "1" (THS1) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

THS2 (TP18 variant 2): TP18 prototype variant "2" (THS2) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

THS3 (TP18 variant 3): TP18 prototype variant "3" (THS3) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

THS4 (TP18 variant 4): TP18 prototype variant "4" (THS4) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.

THS5 (THS 3.0 reference device): THS 3.0 device (reference) and the corresponding tobacco sticks will be provided by the Sponsor. There are two variants of the sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants may choose either variant or both.

CIG (Cigarette): Current cigarette smokers will use their usual brand of commercially available CIG.

Study summary

This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.

Eligibility

Sex
ALL
Min age
21 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participant has signed the ICF and understands the information provided in it. * Participant is male or female and between 21 and 65 years old (inclusive). * Participant has been a smoker for at least 2 years prior to the screening visit and is willing to switch to THS and TP18. * Participant has smoked on average ≥10 commercially available CIGs/day over the last 30 days. Smoking status will be verified based on a urinary cotinine test (cotinine ≥200 ng/mL). * Participant does not plan to quit smoking within the next three months. * Participant is available for the entire study period and willing to comply with the study procedures, including product use assignments and periods of abstinence from any nicotine/tobacco-containing products, and willing to adhere to a standardized diet (during confinement period and during overnight stays on Day 30 and Day 60). Exclusion Criteria: * As per the Investigator's judgment, the participant cannot participate in the study for any reason other than medical (e.g., psychological, social reason). * Participant is legally incompetent, or physically or mentally incapable of giving consent (e.g., in emergency situations, under guardianship, prisoners). * Participant has a health condition which requires medication or any other clinically relevant finding based on available assessments from the Screening period (e.g., safety panel, pulmonary function test, vital signs, physical examination, ECG, and medical history), as determined by the Principal Investigator or designee. * Participant experienced within 30 days prior to screening/admission a body temperature \>37.9°C or an acute illness (e.g., upper respiratory-tract infection, viral infection, etc.). * According to the Investigator's judgment, the participant has medical conditions that require or will require medical intervention (e.g., initiation of treatment, surgery, hospitalization) during the study period, which may interfere with study participation and/or study results. * Participant uses medication that aids in smoking cessation. * Participant experiences difficulty with venipuncture and/or poor venous access. * Participant has a hemoglobin level \< 11.0 g/dL for females and \< 12.0 g/dL for males at the Screening visit. * Participant has a positive nitrite urinary test at screening or on admission day (Day -2) * Participant has donated blood or received whole blood or blood products within the past 3 months. * BMI \< 18.5 kg/m2 or ≥ 32.0 kg/m2. * Positive serology test for HIV 1/2, HBV, or HCVa. * Participant has a positive alcohol breath test and/or has a history of alcohol disorder that could interfere with their participation in the study. * The participant has a positive urine drug test. * Participant or one of their family members is a current or former employee of the tobacco industry, manufacturing or distributing e-cigarettes or other nicotine/tobacco-containing products. * A participant or a family member is an employee of the investigational site or of any other parties involved in the study. * Participant has participated in another clinical study within 30 days or within a period equivalent to five half-lives of the investigational product from that study, whichever is longer. . * Participant has been previously screened or enrolled in this study (unless they are alternate subjects). * Female participant is pregnant (does not have negative pregnancy tests at screening and/or at admission) or is breastfeeding. * For women of childbearing potential only and males: participant does not agree to use an acceptable method of effective contraception.

Primary outcome measure(s)

  • 3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (confinement period) — Measured from Day -1 to Day 5.
    Concentrations of 3-HPMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
  • 2-cyanoethyl mercapturic acid N-acetyl-S-(2-cyanoethyl)-L-cysteine (2-CyEMA) in Urine (confinement period) — Measured from Day -1 to Day 5.
    Concentrations of 2-CyEMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
  • Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (confinement period) — Measured from Day -1 to Day 5.
    Concentrations of MHBMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
  • Total N-nitrosonornicotine (total NNN) in Urine (confinement period) — Measured from Day -1 to Day 5.
    Concentrations of total NNN measured in 24-hour urine and expressed as concentration adjusted for creatinine.
  • Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in Urine (confinement period) — Measured from Day -1 to Day 5.
    Concentrations of total NNAL measured in 24-hour urine and expressed as concentration adjusted for creatinine.
  • Carboxyhemoglobin (COHb) in Blood (confinement period) — Measured from Day -1 to Day 5.
    Carboxyhemoglobin (COHb) is assayed from whole blood and expressed as percentage of the total hemoglobin saturated with carbon monoxide.

Trial sites (1)

FacilityCityRegionStatus
Celerion Belfast United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07443631 on ClinicalTrials.gov ↗ ← All trials in the UK